Drug
MEDI-534
MEDI-534 is a pharmaceutical drug with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
33%(1 trials)
Phase Distribution
Ph phase_1
2
67%
Phase Distribution
2
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution2 total trials
Phase 1Safety & dosage
2(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(3)
Detailed Status
Completed3
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 1
Trials by Phase
Phase 12 (100.0%)
Trials by Status
completed3100%
Recent Activity
0 active trials
Showing 3 of 3
completedphase_1
Safety and Tolerability Study to Evaluate MEDI-534 in Children 6 to < 24 Months of Age
NCT00493285
completedphase_1
Study to Evaluate the Safety of MEDI-534 Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3) in Healthy Children
NCT00345670
completed
Study to Evaluate MEDI-534 in Healthy Adults
NCT00111878
Clinical Trials (3)
Showing 3 of 3 trials
NCT00493285Phase 1
Safety and Tolerability Study to Evaluate MEDI-534 in Children 6 to < 24 Months of Age
NCT00345670Phase 1
Study to Evaluate the Safety of MEDI-534 Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3) in Healthy Children
NCT00111878
Study to Evaluate MEDI-534 in Healthy Adults
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3